IGF1R and breast cancer: Although ERα is the main driver of breast cancer progression and still the main target for treatment, dysregulation of the IGF-1R/phosphatidylinositol-3-kinase (PI3K)/Akt pathway has been shown to correlate with breast cancer development and has been intensively studied as a potential therapeutic target (42–44).